文献速递肝病

机器学习模型CIRI无创预测代偿期晚期慢性肝病首次失代偿

A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: The CIRI model.
PubMed 文献 · J Hepatol · 2026-07-16

本研究开发并验证了基于11项人口学和常规实验室参数的机器学习模型CIRI,用于预测代偿期晚期慢性肝病(cACLD)患者首次失代偿。模型在美国Optum CDM数据库(训练集112,618例,内部验证18,852例)和欧洲前瞻性队列(210例)中验证,1年和2年AUROC在Optum CDM为0.816和0.815,优于MELD和FIB-4;在欧洲队列为0.836和0.769,与HVPG相当且优于LSM。CIRI独立预测失代偿,切点≥-8.25可识别与HVPG≥10 mmHg相当风险的患者。

要点

  • CIRI基于常规实验室和人口学数据,无创预测cACLD首次失代偿。
  • CIRI区分度与HVPG相当,优于LSM、MELD和FIB-4。
  • 切点≥-8.25可识别与HVPG≥10 mmHg相当失代偿风险的患者。

核心结论

  • 机器学习模型CIRI在cACLD患者中展现出稳健的预后性能和准确的风险分层。
  • CIRI对失代偿风险的区分能力与HVPG相当,有望无创识别高危患者。

研究设计与样本

  • 模型开发与内部验证使用美国Optum CDM数据库,训练集112,618例,内部验证集18,852例cACLD患者。
  • 外部验证使用欧洲前瞻性三级医疗队列,包含210例经HVPG评估的cACLD患者。
  • 主要终点为首次失代偿(腹水、肝性脑病、静脉曲张出血),肝细胞癌和死亡为竞争事件。

主要发现

  • Optum CDM中脂肪性肝病为首要病因(54%),中位随访18.5个月(IQR 7.2-40.4);欧洲队列为44%,中位随访27.5个月(IQR 21.2-34.8)。
  • Optum CDM中CIRI的1年和2年时间依赖AUROC分别为0.816和0.815,高于MELD和FIB-4(均p<0.001)。
  • 欧洲队列中CIRI的AUROC分别为0.836和0.769,与HVPG相当(均p>0.900),优于LSM(均p<0.05)。
  • CIRI独立预测失代偿:Optum CDM调整后亚分布风险比(aSHR)1.67(p<0.001);欧洲aSHR 1.66(p=0.017)。
  • 切点≥-8.25识别出的患者失代偿风险与HVPG≥10 mmHg(CSPH)相当。

关键数值与推荐

  • CIRI模型使用11项人口学和常规实验室参数。
  • CIRI切点≥-8.25用于识别与HVPG≥10 mmHg相当失代偿风险的患者。
  • Optum CDM中CIRI的1年和2年AUROC为0.816和0.815;欧洲队列为0.836和0.769。
  • CIRI预测失代偿的aSHR在Optum CDM为1.67(p<0.001),在欧洲为1.66(p=0.017)。

临床怎么用

  • CIRI可基于常规数据无创评估cACLD患者短期失代偿风险,辅助风险分层。
  • 切点≥-8.25可识别高危患者,有助于指导监测强度和预防策略。
  • 在进一步前瞻性验证前,CIRI可作为HVPG和LSM的补充工具。

局限性

  • 研究为模型开发与验证,尚未在前瞻性干预研究中评估CIRI指导管理对临床结局的影响。
  • 外部验证队列样本量较小(210例),需更大规模前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatic venous pressure gradient (HVPG) is the gold standard for assessment of prognosis in compensated advanced chronic liver disease (cACLD), yet its invasiveness limits broad clinical use. We developed and validated the Cirrhosis Risk Identifier (CIRI) model, a machine-learning tool using 11 demographic and routine laboratory parameters trained to prognosticate first decompensation; and benchmarked its performance against HVPG, liver stiffness measurement (LSM), FIB-4 and MELD. METHODS: Patients with cACLD were identified in the US Optum Clinformatics Data Mart (Optum CDM) for model development and internal validation and externally validated in a prospective European tertiary care cohort. The primary endpoint was first decompensation (ascites, encephalopathy, variceal bleeding) with hepatocellular carcinoma and death as competing events. RESULTS: CIRI was trained on 112,618 and internally validated on 18,852 patients with cACLD in Optum CDM, with 210 HVPG-characterized patients with cACLD (European cohort) included for external validation. In both Optum CDM and Europe, steatotic liver disease was the leading etiology (54%; 44%), with median follow-up of 18.5 months (IQR 7.2-40.4) and 27.5 months (21.2-34.8), respectively. In Optum CDM, CIRI showed higher 1- and 2-year time-dependent AUROCs (0.816, 0.815) than MELD and FIB-4 (both p <0.001). In Europe, AUROCs (0.836, 0.769) were comparable to HVPG (both p >0.900) and superior to LSM (both p <0.05). CIRI predicted decompensation independently (Optum CDM: adjusted subdistribution hazard ratio [aSHR]: 1.67, p <0.001; Europe: aSHR: 1.66, p = 0.017) with a cut-off of ≥-8.25 identifying patients at comparable decompensation risk as HVPG ≥10 mmHg (CSPH). CONCLUSION: The machine-learning-based CIRI model yielded robust prognostic performance and accurate risk stratification in patients with cACLD. CIRI's discrimination of decompensation risk was comparable to that of HVPG, highlighting its potential future utility to non-invasively identify "at-risk" patients with cACLD. IMPACT AND IMPLICATIONS: Hepatic decompensation marks the key clinical transition from compensated to decompensated advanced chronic liver disease and is associated with substantially worse prognosis. However, current risk assessment remains limited by the invasiveness of the gold-standard hepatic venous pressure gradient (HVPG) measurement and the infrastructure required for established non-invasive tests such as liver stiffness measurement (LSM). In this study, we developed and validated "Cirrhosis Risk Identifier" (CIRI), a machine-learning model based solely on routine laboratory and demographic data, which predicted first hepatic decompensation with performance comparable to HVPG and superior to widely used non-invasive tests including LSM, MELD and FIB-4. These findings are important for clinicians and researchers aiming to identify patients with cACLD who are at increased short-term risk of hepatic decompensation. Pending further prospective validation, CIRI could support scalable and repeatable risk stratification and help guide surveillance intensity and targeted strategies intended to prevent hepatic decompensation for high-risk patients. CLINICAL TRIAL NUMBER: NCT03267615.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kramer G, Hildeman A, Tozzi C, et al. A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: The CIRI model. J Hepatol. 2026. PMID: 42462822. doi:10.1016/j.jhep.2026.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。